Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab plus Gebasaxturev and Pembrolizumab Monotherapy in Stage IIIB–D Melanoma By Ogkologos - January 21, 2025 644 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a substudy 02C of the KEYMAKER-U02 trial Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR As Rates of Some Cancers Increase in Younger People, Researchers Search... May 14, 2025 EMA Pharmacovigilance Risk Assessment Committee Advice on Safety-Related Aspects of the... February 19, 2021 EMA Recommends Granting a Marketing Authorisation for Elacestrant July 26, 2023 FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumours August 20, 2021 Load more HOT NEWS FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or... 如何在肺癌患病期间和之后维持性健康 FDA Approves Relugolix for Advanced Prostate Cancer Study Links Breast Cancer Spread to Newly Discovered RNA Splicing Mechanism
